![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /ˌrɛlʊˈɡoʊlɪks/ RE-luu-GOH-liks |
Trade names | Orgovyx, Relumina |
Other names | RGX; RVT-601; TAK-385 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a621006 |
License data | |
Routes of administration | By mouth[1] |
Drug class | GnRH antagonist |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 68–71%[1] |
Elimination half-life | 36 to 65 hours[1] |
Excretion | Feces: 82%[1] Urine: 4%[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H27F2N7O5S |
Molar mass | 623.64 g·mol−1 |
3D model (JSmol) | |
| |
|
Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer in men and uterine fibroids in women.[5][1][7] It is taken by mouth.[1][7]
Side effects of relugolix include menstrual abnormalities, hot flashes, excessive sweating, headache, and decreased bone mineral density.[7][1] Relugolix is a GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone receptor.[1] Unlike most other GnRH modulators, but similarly to elagolix (brand name Orilissa), relugolix is a non-peptide, small-molecule compound and is orally active.[8][9][10] It suppresses sex hormone levels to the postmenopausal or castrate range in both women and men.[1][11][5]
Relugolix was approved for use for the treatment of uterine fibroids in Japan in January 2019, and for the treatment of prostate cancer in the United States in December 2020.[12][13]
Orgovyx EPAR
was invoked but never defined (see the help page).pmid21657270
was invoked but never defined (see the help page).pmid24333551
was invoked but never defined (see the help page).pmid29232843
was invoked but never defined (see the help page).pmid26502357
was invoked but never defined (see the help page).PRNewswire2019
was invoked but never defined (see the help page).